Cargando…
Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
Autores principales: | Catanese, Silvia, Lordick, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812228/ https://www.ncbi.nlm.nih.gov/pubmed/33490213 http://dx.doi.org/10.21037/atm-20-4438 |
Ejemplares similares
-
Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
por: Rotte, Anand
Publicado: (2023) -
Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019) -
100 Already?
por: Negrin, Robert S.
Publicado: (2021) -
Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma
por: Rakké, Yannick Sebastiaan, et al.
Publicado: (2020) -
What we learned from STEP that we didn't already know from SPRINT
por: Modesti, Pietro Amedeo
Publicado: (2021)